Welcome!

News Feed Item

Janssen Initiates CREDENCE Study in Patients with Type 2 Diabetes and Diabetic Nephropathy

Trial Seeks to Examine the Effects of INVOKANA® on the Progression of Diabetic Nephropathy

RARITAN, N.J., Feb. 21, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced the initiation of CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation), a global, multicenter study of INVOKANA® (canagliflozin). This Phase 3 study is a randomized, double-blind, placebo-controlled, parallel group trial designed to enroll more than 3,700 patients with type 2 diabetes and diabetic nephropathy. The objective of the study is to examine whether canagliflozin can slow the progression of diabetic nephropathy, a form of renal impairment that is the most common cause of end-stage renal disease worldwide.

"Nearly one-third of all patients with type 2 diabetes will develop evidence of nephropathy. Despite the availability of existing therapies proven to slow its progression, diabetic nephropathy is associated with a 36 percent mortality rate over a five-year period," said Norman Rosenthal, MD, FACE, FACP, canagliflozin compound development team leader, Janssen. "Clearly, patients need new, safe and effective treatment options. We look forward to determining if canagliflozin can be used to treat diabetic nephropathy, as we continue to assess additional uses for canagliflozin."

The CREDENCE trial will evaluate patients with type 2 diabetes and diabetic nephropathy receiving standard of care, which includes treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers. The trial's composite primary endpoint includes a doubling of serum creatinine, the occurrence of end-stage renal failure and cardiovascular death. Janssen is partnering with The George Institute, a leading Academic Research Organization based in Sydney, Australia, to provide academic leadership for the study.

About INVOKANA®
INVOKANA® is the first sodium glucose co-transporter 2 (SGLT2) inhibitor available in the United States (U.S.). It is an oral medication that selectively inhibits SGLT2, a cell transporter responsible for the reabsorption of glucose by the kidney, thereby promoting the loss of glucose in the urine and lowering blood glucose levels in adults with type 2 diabetes.

In March 2013, the FDA approved INVOKANA® as a single agent as an adjunct to diet and exercise to lower blood sugar in adults with type 2 diabetes. INVOKANA® has since been widely adopted and today it is the number one branded therapy prescribed by U.S. endocrinologists when adding or switching non-insulin type 2 diabetes medications.[1] More than a half a million prescriptions have now been written for INVOKANA® in the U.S. since its approval in March 2013. In November 2013, the European Commission approved INVOKANA® for adults aged 18 years and older with type 2 diabetes mellitus to improve glycemic control. INVOKANA® has also been approved in Australia, Chile, Mexico and Switzerland.

INVOKANA® has been studied as monotherapy and in combination with other type 2 diabetes therapies. The comprehensive global Phase 3 clinical development program for INVOKANA® enrolled 10,285 patients in nine studies and was one of the largest clinical programs in type 2 diabetes submitted to health authorities to date. In two separate trials, INVOKANA® 300mg demonstrated greater reductions in A1C versus sitagliptin 100mg at 52 weeks, as well as greater reductions in body weight and systolic blood pressure. The recommended starting dose on INVOKANA® is 100mg. A1C is the percent of red blood cell hemoglobin with glucose attached to it and an indicator of average blood glucose over the previous two to three months.

The most common adverse events with INVOKANA® are genital mycotic (fungal) infections, urinary tract infections and increased urination. These specific adverse events were generally mild to moderate in intensity and infrequently led to discontinuation in Phase 3 studies.

About Type 2 Diabetes and Diabetic Nephropathy
Type 2 diabetes is a chronic condition that affects the body's ability to metabolize sugar, or glucose, and is characterized by the inability of pancreatic beta cell function to keep up with the body's demand for insulin.[2] The International Diabetes Federation estimates that in 2013, 382 million people were living with diabetes (type 1 and 2) and the diabetes population is expected to grow to over 592 million in less than 20 years.[3] The World Health Organization estimates that 90 percent of the diabetes population has type 2 diabetes.[4]

Patients with type 2 diabetes can develop severe complications. Diabetic nephropathy (renal impairment) is a potential complication of type 2 diabetes and is characterized by persistent albuminuria (protein in the urine) and a progressive decline in renal function. Diabetes is the primary cause of end-stage renal disease.[5]

Approximately 44 percent of patients beginning dialysis in the U.S. have diabetes, so early diagnosis and treatment is important to potentially prevent progression to renal failure.[5] Approximately 20 – 30 percent of all patients with type 2 diabetes will develop evidence of nephropathy; however, fewer type 2 diabetes patients actually progress to end stage renal disease.[5]

INDICATION STATEMENT
WHAT IS INVOKANA®?

  • INVOKANA® is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
  • INVOKANA® is not for people with type 1 diabetes.
  • INVOKANA® is not for people with diabetic ketoacidosis (increased ketones in blood or urine).
  • It is not known if INVOKANA® is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT INVOKANA®?
INVOKANA® can cause important side effects, including:

  • Dehydration. INVOKANA® can cause some people to have dehydration (the loss of body water and salt). Dehydration may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension).

You may be at higher risk of dehydration if you:

    • have low blood pressure
    • take medicines to lower your blood pressure, including diuretics (water pill)
    • are on low sodium (salt) diet
    • have kidney problems
    • are 65 years of age or older
  • Vaginal yeast infection. Women who take INVOKANA® may get vaginal yeast infections. Symptoms of a vaginal yeast infection include:
    • vaginal odor
    • white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese)
    • vaginal itching
  • Yeast infection of the penis (balanitis or balanoposthitis). Men who take INVOKANA® may get a yeast infection of the skin around the penis. Certain men who are not circumcised may have swelling of the penis that makes it difficult to pull back the skin around the tip of the penis. Other symptoms of yeast infection of the penis include:
    • redness, itching, or swelling of the penis
    • rash of the penis
    • foul smelling discharge from the penis
    • pain in the skin around penis

Talk to your doctor about what to do if you get symptoms of a yeast infection of the vagina or penis. Your doctor may suggest you use an over-the-counter antifungal medicine. Talk to your doctor right away if you use an over-the-counter antifungal medication and your symptoms do not go away.

WHO SHOULD NOT TAKE INVOKANA®?
Do not take INVOKANA
® if you:

  • are allergic to canagliflozin or any of the ingredients in INVOKANA®. See the end of the Medication Guide for a list of ingredients in INVOKANA®. Symptoms of allergic reaction to INVOKANA® may include:
    • rash
    • raised red patches on your skin (hives)
    • swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing
  • have severe kidney problems or are on dialysis

WHAT SHOULD I TELL MY DOCTOR BEFORE TAKING INVOKANA®?
Before you take INVOKANA®, tell your doctor if you:

  • have kidney problems
  • have liver problems
  • are on a low sodium (salt) diet. Your doctor may change your diet or your dose of INVOKANA®.
  • have ever had an allergic reaction to INVOKANA®
  • have other medical conditions
  • are pregnant or plan to become pregnant. It is not known if INVOKANA® will harm your unborn baby. If you are pregnant, talk with your doctor about the best way to control your blood sugar while you are pregnant.
  • are breastfeeding or plan to breastfeed. It is not known if INVOKANA® passes into your breast milk. Talk with your doctor about the best way to feed your baby if you are taking INVOKANA®.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

INVOKANA® may affect the way other medicines work, and other medicines may affect how INVOKANA® works. Especially tell your doctor if you take:

  • diuretics (water pills)
  • rifampin (used to treat or prevent tuberculosis)
  • phenytoin or phenobarbital (used to control seizures)
  • ritonavir (Norvir®, Kaletra®, Lopinavir®)* (used to treat HIV infection)
  • digoxin (Lanoxin®)* (used to treat heart problems)

Ask your doctor or pharmacist for a list of these medicines if you are not sure if your medicine is listed above.

Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

HOW SHOULD I TAKE INVOKANA®?

  • Take INVOKANA® by mouth 1 time each day exactly as your doctor tells you to take it.
  • Your doctor will tell you how much INVOKANA® to take and when to take it. Your doctor may change your dose if needed.
  • It is best to take INVOKANA® before the first meal of the day.
  • Your doctor may tell you to take INVOKANA® along with other diabetes medicines. Low blood sugar can happen more often when INVOKANA® is taken with certain other diabetes medicines. See "What are the possible side effects of INVOKANA®?"
  • If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take two doses of INVOKANA® at the same time. Talk to your doctor if you have questions about a missed dose.
  • If you take too much INVOKANA®, call your doctor or go to the nearest hospital emergency room right away. When your body is under some types of stress, such as fever, trauma (such as a car accident), infection, or surgery, the amount of diabetes medicine you need may change. Tell your doctor right away if you have any of these conditions and follow your doctor's instructions.
  • Stay on your prescribed diet and exercise program while taking INVOKANA®.
  • Check your blood sugar as your doctor tells you to.
  • INVOKANA® will cause your urine to test positive for glucose.
  • Your doctor may do certain blood tests before you start INVOKANA® and during treatment as needed. Your doctor may change your dose of INVOKANA® based on the results of your blood tests.
  • Your doctor will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin A1C.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF INVOKANA®?
INVOKANA® may cause serious side effects, including:
See "What is the most important information I should know about INVOKANA®?"

  • kidney problems
  • a high amount of potassium in your blood (hyperkalemia)
  • low blood sugar (hypoglycemia). If you take INVOKANA® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take INVOKANA®.

Signs and symptoms of low blood sugar may include:

  • headache
  • drowsiness
  • weakness
  • dizziness
  • confusion
  • irritability
  • hunger
  • fast heartbeat
  • sweating
  • shaking or feeling jittery
  • serious allergic reaction. If you have any symptoms of a serious allergic reaction, stop taking INVOKANA® and call your doctor right away or go to the nearest hospital emergency room. See "Who should not take INVOKANA®?". Your doctor may give you a medicine for your allergic reaction and prescribe a different medicine for your diabetes.

The most common side effects of INVOKANA® include:

  • vaginal yeast infections and yeast infections of the penis (See "What is the most important information I should know about INVOKANA®?")
  • urinary tract infection
  • changes in urination, including urgent need to urinate more often, in larger amounts, or at night

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of INVOKANA®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Janssen Scientific Affairs, LLC at 1-800-526-7736.

Please see the full Prescribing Information and Medication Guide.

Trademarks are those of their respective owners.

About Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development, LLC and Janssen Scientific Affairs, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com for more information.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.

[1] Data on file. Based on NBRx data sourced from IMS NPA Market Dynamics Database, weekly data through 9/20/13.

[2] International Diabetes Federation. About Diabetes. Available: http://www.idf.org/about-diabetes. Last accessed: Feb 2013.

[3] International Diabetes Federation. Diabetes: Facts and Figures. Available: http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures. Last accessed: January 2014.

[4] Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, World Health Organization, 1999 (WHO/NCD/NCS/99.2).

[5] Cleveland Clinic. Diabetic Neuropathy. Available: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/diabetic-nephropathy/#prevalence. Last accessed: January 2014.

Media contacts:
Christina Chan
Phone: (908) 927-5769
[email protected]

Christina Holden
Phone: (908) 927-3581
[email protected]

Investor contacts:
Stan Panasewicz
Phone: (732) 524-2524

Louise Mehrotra
Phone: (732) 524-6491

SOURCE Janssen Research & Development, LLC

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Redis is not only the fastest database, but it has become the most popular among the new wave of applications running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 18th Cloud Expo, Dave Nielsen, Developer Relations at Redis Labs, shared the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, will share examples from a wide range of industries – includin...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, showed how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningful f...
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effici...
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...